All In Biotech

Drug Trial Radar · NCT05156983

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial With Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation in Patients Requiring Urgent Surgery/Invasive Procedure

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

440

Planned (sponsor's estimate)

Start

Aug 24, 2022

Primary completion

Aug 30, 2028

Study completion Aug 30, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Dec 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure. The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery. Patients participating in this study will need to be hospitalized. They will also be contacted (via telehealth/phone call) 30 days after the surgery.

Conditions

  • Coagulation Disorder

Interventions

  • TAK-330Drug

    Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.

  • SOC 4F-PCCDrug

    Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Intraoperative Effective HemostasisTime frame: At the end of the surgery/procedure

Locations

64 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Arkansas Medical Sciences

    Arkansas City, Arkansas · Recruiting

  • University of California Davis Health System

    Sacramento, California · Recruiting

  • Denver Metro Orthopedics, P.C.

    Englewood, Colorado · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Rutgers, The State University of New Jersey

    New Brunswick, New Jersey · Recruiting

  • ECU Health Medical Center

    Greenville, North Carolina · Recruiting

  • Metro Health Medical Center

    Cleveland, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Ascension St. John Medical Center

    Tulsa, Oklahoma · Recruiting

  • University of Pennsylvania - Perelman School of Medicine

    Philadelphia, Pennsylvania · Recruiting

  • UPMC

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Carilion Medical Center

    Virginia Beach, Virginia · Recruiting

  • Hospital Universitario Austral

    Buenos Aires, Argentina · Recruiting

  • Clinica Zabala

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia - FLENI

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Hospital Privado de Rosario

    Santa Fe, Argentina · Recruiting

  • LKH - Universitaetsklinikum Graz

    Graz, Austria · Recruiting

  • Landesklinikum Neunkirchen

    Neunkirchen, Austria · Recruiting

  • AZ Groeninge

    Kortrijk, Belgium · Recruiting

  • CHU UCL Namur

    Therasse 1, Belgium · Recruiting

  • ZOL

    Genk, Limburg, Belgium · Recruiting

  • Jessa Ziekenhuis Hospital

    Hasselt, Limburg, Belgium · Recruiting

  • Hospital de Clinicas de Ijui

    Ijuí, Brazil · Recruiting

  • Hospital Sao Paulo

    São Paulo, Brazil · Recruiting

  • Irmandade da Santa Casa da Misericordia de Santos

    Santos, São Paulo, Brazil · Recruiting

  • The Ottawa Hospital - General Campus

    Ontario, Canada · Recruiting

  • CHU de Quebec- Hopital de l Enfant Jesus

    Québec, Canada · Recruiting

  • Hamilton General Hospital

    Hamilton, Ontario, Canada · Recruiting

  • London Health Sciences Centre (LHSC) - University Hospital

    London, Ontario, Canada · Recruiting

  • Unity Health Toronto St Michaels Hospital

    Toronto, Ontario, Canada · Recruiting

  • Montreal General Hospital

    Montreal, Quebec, Canada · Recruiting

  • Fakultni nemocnice Brno

    Jihlavska, Czechia · Recruiting

  • Fakultni nemocnice v Motole

    Prague (Praha), Czechia · Recruiting

  • Dept of II. interni klinika - gastroenterologie

    Srobarova C, Czechia · Recruiting

  • Hospital michallon - CHUGA

    Grenoble, France · Completed

  • Hopital Marie Lannelongue

    Le Plessis-Robinson, France · Completed

  • Hôpital Lariboisière

    Paris, France · Completed

  • GH Paris Saint Joseph

    Paris, France · Recruiting

  • CHU Strasbourg - Hopital Hautepierre

    Strasbourg, Bas Rhin, France · Recruiting

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.